What's next in urology — November 16, 2026
Three upcoming dates in urology, from December 2026 to March 2027: a company-announced presentation of PIVOT-006, a phase 3 trial in intermediate-risk non-muscle-invasive bladder cancer (NMIBC), and the ASCO GU and EAU congresses. The specific content of the two congresses will depend on their confirmed programmes. Announcements without an official date and events that have already happened were excluded.
1. PIVOT-006 at SUO: adjuvant cretostimogene in intermediate-risk NMIBC
[Congress presentation] [North America] [Announced date: December 2, 2026, per CG Oncology]
What it is: CG Oncology announces a PIVOT-006 presentation for December 2, 2026, as a late-breaking podium presentation at the Society of Urologic Oncology (SUO) Annual Meeting. Topline results were already reported on November 16. The upcoming milestone is the presentation, which does not constitute peer-reviewed publication. PIVOT-006 is an open-label, 1:1 randomized phase 3 trial (NCT06111235) comparing intravesical cretostimogene grenadenorepvec (an oncolytic adenovirus) after TURBT with surveillance in intermediate-risk NMIBC and high-grade Ta ≤3 cm; more than 360 patients at more than 90 sites; primary endpoint: recurrence-free survival. In the same announcement, the company expects to complete its BLA for BCG-unresponsive NMIBC before the end of March 2027.
What problem it solves: intermediate-risk disease recurs often and accumulates repeat TURBTs; current options are intravesical chemotherapy (mitomycin, gemcitabine) or BCG, the latter under chronic shortage.
Critical take: open-label and company-sponsored; so far the results are known only from a press release, without peer review; the presentation date comes from the company's announcement, and complete results at SUO should not be taken for granted; the comparator is surveillance, not active intravesical chemotherapy.
Sources
- [Official release] CG Oncology, November 16, 2026 (PIVOT-006 topline results and announced SUO presentation). https://ir.cgoncology.com/news-releases/news-release-details/pivot-006-phase-3-registrational-trial-demonstrates
- [Coverage] OncLive, November 16, 2026. https://www.onclive.com/view/cretostimogene-improves-rfs-in-intermediate-risk-and-high-grade-ta-nmibc
- [Official release] CG Oncology, September 3, 2025 (completion of PIVOT-006 enrollment; reproduced on BioSpace). https://www.biospace.com/press-releases/cg-oncology-completes-enrollment-in-pivot-006
- [Registry] NCT06111235, ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06111235
2. ASCO GU 2027
[Congress] [US] [Confirmed date: February 11, 2027]
What it is: the ASCO Genitourinary Cancers Symposium, February 11–13, 2027, at Moscone West, San Francisco; ASCO's annual meeting devoted to prostate, bladder and kidney cancer, among others.
What problem it solves: it is typically where trials known only from press releases are presented in detail, allowing assessment of effect size, toxicity and subgroups.
Critical take: the specific content will depend on the confirmed programme, and a congress presentation does not replace peer-reviewed publication.
Sources
- [Meeting] Moscone Center, events calendar: American Society of Clinical Oncology GU Cancers Symposium 2027, February 11–13, 2027. https://moscone.com/events/american-society-clinical-oncology-gu-cancers-symposium-2027
- [Meeting] ASCO GU 2027, exhibitor document on the Industry Expert Theaters (sessions on February 11 and 12, 2027). https://events.jspargo.com/GU27/CUSTOM/PDF27/GU2027IET.pdf
3. EAU27: Annual Congress of the European Association of Urology
[Congress] [Europe] [Confirmed date: March 19, 2027]
What it is: the 42nd Annual EAU Congress, March 19–22, 2027, at Amsterdam RAI; the late-breaking abstract window opens December 21, 2026, closes January 23, 2027, and outcomes are communicated February 12, 2027.
What problem it solves: it is the annual congress of the specialty's European society, and the late-breaking session is reserved for novel, time-sensitive data of major scientific importance.
Critical take: the EAU requires final data and does not accept preliminary or incomplete data, but congress presentations do not replace peer-reviewed publication.
Sources
- [Meeting] EAU, 42nd Annual EAU Congress, March 19–22, 2027. https://uroweb.org/education-events/42nd-annual-eau-congress
- [Meeting] EAU27, abstract submission (late-breaking abstracts: December 21, 2026 to January 23, 2027). https://eaucongress.uroweb.org/scientific-programme/abstract-submission
Ready-to-paste WhatsApp text
*What's next in urology — November 16, 2026* 1. PIVOT-006 (adjuvant cretostimogene vs surveillance, intermediate-risk NMIBC): SUO presentation on December 2, 2026, announced by CG Oncology; topline results were already reported on November 16. 2. ASCO GU 2027, San Francisco: February 11–13, 2027. 3. EAU27, Amsterdam: March 19–22, 2027 (late-breaking abstracts due January 23). Full text and audio: https://boletinesmedicos.com/en/urology/2026-11-16-viene.html MedBulletins · boletinesmedicos.com
Ready-to-paste LinkedIn post
What's next in urology (December 2026 – March 2027), three dates with an official source: • PIVOT-006: phase 3 of adjuvant cretostimogene vs surveillance in intermediate-risk non-muscle-invasive bladder cancer. CG Oncology announces its SUO presentation on December 2, 2026; topline results were already reported by press release on November 16 (open-label, sponsored; the presentation does not constitute peer-reviewed publication). • ASCO GU 2027, San Francisco, February 11–13. • EAU27, Amsterdam, March 19–22. The specific content of ASCO GU and EAU27 will depend on their confirmed programmes. What each item is, what problem it solves, and a critical take: https://boletinesmedicos.com/en/urology/2026-11-16-viene.html #Urology #BladderCancer #UroOncology #EAU27 #ASCOGU
Ready-to-paste X (Twitter) post
What's next in urology: PIVOT-006 at SUO (Dec 2, per CG Oncology), ASCO GU (Feb 11–13) and EAU27 (Mar 19–22). With critical take: https://boletinesmedicos.com/en/urology/2026-11-16-viene.html
Get every issue by email
Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.